SCHEMBL6317620

SCHEMBL6317620

CN(C)Cc1ccc(NNC=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.47
HDAC3 O15379 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.42
TAAR1 Q96RJ0 2/20 0.41
LSS P48449 2/20 0.41
BPTF Q12830 1/20 0.38
HDAC4 P56524 1/20 0.36
MEF2D Q14814 1/20 0.36
BRD4 O60885 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
MMP9 P14780 1/20 0.33
TTK P33981 1/20 0.33
AURKB Q96GD4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325838 0.82 HRH3 (0.50) HRH3HDAC6BCHEACHE
SCHEMBL8761098 0.79 GAA (0.44) HDAC3HDAC6ALDH1A1HDAC4
SCHEMBL8761084 0.76 EPHX1 (0.31)
SCHEMBL8102350 0.76 HRH3 (0.54) HRH3HDAC3HDAC6ALDH1A1TSHR
SCHEMBL9785851 0.75 CYP2A6 (0.48) ALDH1A1TSHR
SCHEMBL24677481 0.73 ADH1B (0.55) HRH3HDAC3HDAC6ALDH1A1TSHR
SCHEMBL659509 0.72 HRH3 (0.82) HRH3HDAC3HDAC6ALDH1A1TSHR
SCHEMBL8761089 0.72 CA2 (0.43) ALDH1A1TSHR
SCHEMBL28247922 0.71 LSS (0.46) HRH3HDAC3HDAC6ALDH1A1TSHR
SCHEMBL9970753 0.71 HRH3 (0.58) HRH3HDAC3HDAC6ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES Boehringer Ingelheim Pharma KG (DE) 2001-07-18 EP disclosed
WO-2000018734-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 HRH3 1204/4885HDAC3 552/4885HDAC6 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.